WARFARIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Warfarin Sodium patents expire, and when can generic versions of Warfarin Sodium launch?
Warfarin Sodium is a drug marketed by Amneal Pharms, Aurobindo Pharma Usa, Barr, Chartwell Rx, Invagen Pharms, Ipca Labs Ltd, Pliva, Taro, Usl Pharma, Watson Labs, and Zydus Pharms Usa. and is included in seventeen NDAs.
The generic ingredient in WARFARIN SODIUM is warfarin sodium. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Warfarin Sodium
A generic version of WARFARIN SODIUM was approved as warfarin sodium by TARO on July 15th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WARFARIN SODIUM?
- What are the global sales for WARFARIN SODIUM?
- What is Average Wholesale Price for WARFARIN SODIUM?
Summary for WARFARIN SODIUM
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 17 |
| Finished Product Suppliers / Packagers: | 24 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 38 |
| Patent Applications: | 5,783 |
| Drug Prices: | Drug price information for WARFARIN SODIUM |
| Drug Sales Revenues: | Drug sales revenues for WARFARIN SODIUM |
| DailyMed Link: | WARFARIN SODIUM at DailyMed |
See drug prices for WARFARIN SODIUM
Recent Clinical Trials for WARFARIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Amgen | Early Phase 1 |
| Boehringer Ingelheim | N/A |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
Pharmacology for WARFARIN SODIUM
| Drug Class | Vitamin K Antagonist |
| Mechanism of Action | Vitamin K Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for WARFARIN SODIUM
US Patents and Regulatory Information for WARFARIN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | WARFARIN SODIUM | warfarin sodium | TABLET;ORAL | 040301-001 | Jul 15, 1999 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | WARFARIN SODIUM | warfarin sodium | TABLET;ORAL | 090935-005 | May 25, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | WARFARIN SODIUM | warfarin sodium | TABLET;ORAL | 040196-004 | Sep 30, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
